Kyntra Bio's total assets for Q1 2026 were $109.63M, a decrease of -8.33% from the previous quarter. KYNB total liabilities were $118.92M for the fiscal quarter, a 3.30% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.